vimarsana.com

Latest Breaking News On - Asaf zviran - Page 2 : vimarsana.com

C2i Genomics Announces Successful Evaluation of Whole Genome-Based Residual Disease Test Across Multiple Solid Cancer models

BioPharma

Asaf zviranBeyondbio innovation hubMinimal residual diseaseKarkinos healthcareNuprobe global

C2i Genomics, Karkinos Healthcare Partner to Bring AI-Powered Cancer R&D to India

C2i Genomics & Karkinos Healthcare to develop the first whole-genome sequencing (WGS) MRD test that will further R&D efforts in India.

Asaf zviranKarkinos healthcare partnerShould knowKarkinos healthcarePowered cancer detectionGenomic saas

AI-Powered Cancer Monitoring Test Launched Across Europe

C2i Genomics launches minimal residual disease test across Europe.

New yorkUnited statesUnited kingdomAsaf zviranGustave roussyAmerican association for cancer researchEuropean unionAmerican associationCancer researchNew orleansIllumina novaseqSoutheast asiaTwist bioscience

7 Israeli Startups Named 2021 Most Promising Digital Health Firms

The startups were named to the Digital Health 150, an annual ranking of companies using digital tech to transform the healthcare industry.

New yorkUnited statesUnited kingdomRamat ganTel avivNew zealandTamir wolfAvi smilaArnon toussia cohenEzra soferAdam rimonAviv navaDotan asselmannAndrea piacquadioHila goldman aslanBrian lee

A Blood Test That Can Identify Recurrent Cancer | The Baltimore Times Online Newspaper

A Blood Test That Can Identify Recurrent Cancer | The Baltimore Times Online Newspaper
baltimoretimes-online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from baltimoretimes-online.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesIsrael generalUnited kingdomShaare zedekAsaf zviranBoris oklanderNatureand merckIdan landauYork genome centerWeizmann institute of scienceDuquesne family officeIsrael institute of technologyShaare zedek medical centerTechnion israel instituteWeizmann institute

vimarsana © 2020. All Rights Reserved.